The responsibility for safe administration of medications has expanded to include the patient as well as the physician and the pharmacist. One method to promote this expansion in responsibility is the creation of labeling information specifically for the patient. In December 1998, the Food and Drug Administration (FDA) published a Final Rule on the requirements for “Medication Guides ” for prescription drug products. This regulation became effective on June 1, 1999. Janssen Phurmaceutica S drug product, Propulsi8, was determined to be appropriate to carry a Medication Guide even before the regulation went into effect. Therefore, Propulsi8 was one of the first drug products to undergo the process of creation, approval, and initial disseminat...
Out-of-date or incomplete drug product labeling information may increase the risk of otherwise preve...
Class of 2018 AbstractObjective: In 2006, the Food and Drug Administration (FDA) outlined standards ...
International audienceThis paper reviews the main tools for communicating benefit–risk medicines inf...
The US Food and Drug Administration (FDA) is developing a new framework to provide patients with qua...
SUMMARY: The Food and Drug Administration (FDA) is amending its regulations governing the content an...
Physician-directed pharmaceutical advertising is regulated in the United States by the Food and Drug...
The US Food and Drug Administration (FDA) is developing a new framework to provide patients with qua...
The standard way in which directions are represented on dispensing labels can be misinterpreted. Err...
In May 2005, the Food and Drug Administration (FDA) issued draft guidance on the type of information...
It has been more than ten years since the Food and Drug Administration proposed regulations which wo...
The Food and Drug Administration (FDA) is responsible for assuring that drugs, devices, and biologic...
Contains fulltext : 176982.pdf (publisher's version ) (Closed access)During clinic...
Purpose: The communication by pharmaceutical companies of promotional messages about their products ...
As one of only two countries that permit direct-to-consumer advertising (DTCA) of pharmaceuticals, t...
Abstract Background Dispensed prescription medicine labels (prescription labels) are important infor...
Out-of-date or incomplete drug product labeling information may increase the risk of otherwise preve...
Class of 2018 AbstractObjective: In 2006, the Food and Drug Administration (FDA) outlined standards ...
International audienceThis paper reviews the main tools for communicating benefit–risk medicines inf...
The US Food and Drug Administration (FDA) is developing a new framework to provide patients with qua...
SUMMARY: The Food and Drug Administration (FDA) is amending its regulations governing the content an...
Physician-directed pharmaceutical advertising is regulated in the United States by the Food and Drug...
The US Food and Drug Administration (FDA) is developing a new framework to provide patients with qua...
The standard way in which directions are represented on dispensing labels can be misinterpreted. Err...
In May 2005, the Food and Drug Administration (FDA) issued draft guidance on the type of information...
It has been more than ten years since the Food and Drug Administration proposed regulations which wo...
The Food and Drug Administration (FDA) is responsible for assuring that drugs, devices, and biologic...
Contains fulltext : 176982.pdf (publisher's version ) (Closed access)During clinic...
Purpose: The communication by pharmaceutical companies of promotional messages about their products ...
As one of only two countries that permit direct-to-consumer advertising (DTCA) of pharmaceuticals, t...
Abstract Background Dispensed prescription medicine labels (prescription labels) are important infor...
Out-of-date or incomplete drug product labeling information may increase the risk of otherwise preve...
Class of 2018 AbstractObjective: In 2006, the Food and Drug Administration (FDA) outlined standards ...
International audienceThis paper reviews the main tools for communicating benefit–risk medicines inf...